Press Release

Nirogy Therapeutics Appoints Simon Pedder, Ph.D., as Chief Executive Officer

Appointment Strengthens Leadership and Expertise to Drive Lead Oncology Program into Phase 1 Clinical Development Founding Chief Executive Officer Dr. Vincent Sandanayaka transitions to role of President and Chief Scientific Officer Boston, Jan. 12, 2022 — Nirogy Therapeutics (“Nirogy” or “the Company”), a privately-held biotechnology company developing novel small molecules to target cellular transporters, today …

Nirogy Therapeutics Appoints Simon Pedder, Ph.D., as Chief Executive Officer Read More »

Sporos Bioventures Announces Formation of Strategic Advisory Board

Dr. Doug Williams to Chair SAB Inaugural members include Drs. Keith Flaherty, Bing Yao, and Doug Hanahan to advise on company’s growing pipeline and discovery engine HOUSTON, Texas., January 11, 2022 — Sporos Bioventures, LLC, (“Sporos” or the “Company”) a private biotechnology company catalyzing the rapid development of potential breakthrough therapies that target novel disease …

Sporos Bioventures Announces Formation of Strategic Advisory Board Read More »

Stellanova Therapeutics

Stellanova Therapeutics, Inc. Announces Closing of $15.5 Million Series A Financing

Proceeds will support development of antibody drugs and discovery platform targeting pro-tumorigenic factors produced by fibroblasts in the tumor microenvironment, rendering resistant cancers treatable. Houston, June 3, 2021 – Stellanova Therapeutics, Inc. (“Stellanova”), a biotechnology company advancing cancer therapies targeting the tumor microenvironment, today announced the closing of a $15.5 million Series A financing led by …

Stellanova Therapeutics, Inc. Announces Closing of $15.5 Million Series A Financing Read More »

Asylia Therapeutics News

Asylia Therapeutics, Inc. Announces Closing of $14.5 Million Series A Financing

Proceeds will support development of novel antibody drugs that convert immunologically “cold” tumors into treatable “hot” tumors, with the goal of enhancing effectiveness of cancer immunotherapy.  Houston, May 25, 2021 – Asylia Therapeutics, Inc. (“Asylia”), a development-stage biotechnology company advancing novel immune modulating therapies for cancer and autoimmune diseases, today announced the closing of a $14.5 …

Asylia Therapeutics, Inc. Announces Closing of $14.5 Million Series A Financing Read More »

Scroll to Top